Nicox S.A. has decided to exercise the option to co-promote its glaucoma and ocular hypertension treatment-latanoprostene bunod-with Bausch + Lomb in the United States.
The treatment was licensed by Nicox to Bausch + Lomb-a division of Valeant Pharmaceuticals International- in 2010. Under the agreement, Nicox was granted the option to co-promote the treatment in the United States.
Bausch + Lomb’s phase III clinical program-which is analyzing the nitric oxide (NO)-donating prostaglandin F2-alpha analog treatment-includes two studies, APOLLO and LUNAR, which are pivotal for registration in the United States, according to Nicox.
Valeant recently said that it expects to receive top-line efficacy results from the first of the phase III studies in the third quarter of 2014, and from the second of the studies in the fourth quarter. The company also said the treatment could be launched in the United States in 2016, pending approval from the FDA.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.